Supply chain & logistics
to manage where and how they ship their products. Enter Treshock. Through its work on FDA blockchain pilots, which were based on its Food Trust platform, IBM believes it has developed an understanding of how to make track and trace technologies work at scale across the pharmaceutical supply chain. Unlike the food industry, which is anchored by major retailers, pharma is a balance of manufacturers, distributors and dispensers, none of which have quite the sway Walmart or Carrefour does on the movement of foodstuffs. So, IBM stepped back, reconsidered, and turned their track and trace technology into an open-source utility. “There was great concern that the industry would just turn over the keys to its data or its responsibility to a third-party vendor,” explains Treshock. “That’s one of the challenges you see in commercial solutions for Drug Supply Chain Security Act interoperability – at the end of the day, nobody is really willing to give any one technology company the ability to do it all.” With pharmaceutical knowledge from Merck and open- source expertise from the Linux Foundation, IBM is now working on the track and trace technology being used for the US vaccine supply, as well as the public-facing Health Pass blockchain for recording vaccinations – which can tie individual recipients to specific product batches and distribution routes. “The ability to share this data, to interoperate across the global supply chain, should be a utility, very much like an interstate highway or the global airport system.” Treshock continues. “Federal Express and UPS compete against each other vehemently, but they both use the same roads. The alternative is that they’d each build their own roads, which sounds absurd – but it’s what we’re doing in the data world in general and specifically in life sciences. We rely on these point-to- point connections that we’ve reached our ability to scale. With this road network operating as a not-for- profit entity, participants, potentially competitors, could utilise it without fear of enriching each other.”
Free-flowing supply
The pandemic has gone a long way to breaking the binary opposition of competition and collaboration. Speaking at the IFPMA media briefing on Covid-19 vaccine manufacturing on 23rd April 2021, Roger Connor, president for global vaccines at GlaxoSmithKline and the vaccine CEO representative for Covax, highlighted the work of the Covax manufacturing task force. “These are very complicated products,” he said. “There are hundreds of components and it only takes one of them to be constrained or stopped flowing to bring the supply of the overall vaccine to a halt. We are very keen to get behind the proposals from the task force, which are to continue to look for collaboration, ensuring the free flow of goods, and getting ahead of bottlenecks; monitoring supply and demand to see where the next one is coming and act on it now, rather than reacting to it.”
38
Indeed, when GSK’s vaccine development stalled, its manufacturing arm offered its services to the companies that had beaten GSK to market. It’s not the pharmaceutical industry of 2019 anymore. “If there’s an opportunity for one company to make their capacity available to another, we will do exactly that,” Connor said. “That behaviour is the sort of thing that we’re seeing across the world.” These are still point-to-point connections between companies, so their efficiency is limited, but the willingness to share is unprecedented. According to Shawn Muma, technology research leader for the Digital Supply Chain Institute, the mantra is: ‘don’t waste a good pandemic’. “Enterprise walls are coming down and businesses are looking horizontally across the entire supply chain, versus vertically, as they did in the past,” he says. The best model Handfield’s seen for this is Flex’s ‘Pulse’ global visibility system, which makes it possible for the electronics manufacturer to monitor inventory across its global supply chains instantaneously. The technology, a set of modules that extract and standardise specific data feeds so they can be viewed on a single global dashboard, is simple; convincing companies to use it could be another matter. That said, the attention the Flex system requires companies to devote to assessing their data could help. In Muma’s experience, most businesses are yet to develop a set of data standards, let alone establish a process for identifying and approving what they’re willing to share. Paradoxically, information is being hoarded because of ignorance. He breaks a solution down into three general categories: companies need to sort the data that actually gives them a competitive advantage from the data that might be beneficial to share, though it sits in a grey area, and the data that should be shared because external actors can use it to help improve efficiencies.
“Over time,” he adds, “people realise that a lot of the stuff they put in the protected bucket can in fact be shared without a lot of risk and that they can generate ROI by doing so.”
A lot more than ROI is at stake in the vaccine rollout and in the future model of personalised healthcare, where the raw materials for therapies will be sourced from patients. “In that world,” says Treshock, “we become our own supply chain. Today it’s all about scale, and in that model, companies typically create moats around themselves using information to support their competitive advantage. For personalised medicine, it will be necessary to fluidly share information, because these samples need to be temperature controlled both ways and if there’s a mix up in the final treatment, the consequences will be grievous.” Soon, there could be millions of these shipments travelling on literal and virtual roads. The world has spent the past year practising for them. As much as the treatments, it’s the system for tracking and tracing them that will keep people healthy. ●
World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53
